We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+5.6%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$63.4M
AUM Growth
-$59.2M
Cap. Flow
-$60.8M
Cap. Flow %
-95.9%
Top 10 Hldgs %
87.5%
Holding
35
New
–
Increased
–
Reduced
3
Closed
15

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$9.4M
2
ZLAB icon
Zai Lab
ZLAB
+$9.17M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.61M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$5.87M
5
SLNO
Soleno Therapeutics
SLNO
+$5.69M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Materials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
1
Harmony Biosciences
HRMY
$2.08B
$11.6M 18.37%
368,665
– –
ILMN icon
2
Illumina
ILMN
$29.5B
$11.4M 17.93%
119,196
– –
OCS icon
3
Oculis Holding
OCS
$655M
$9.99M 15.75%
514,702
– –
INCY icon
4
Incyte
INCY
$25.8B
$4.02M 6.34%
59,022
– –
ONC
5
BeOne Medicines Ltd
ONC
$33.9B
$3.81M 6%
15,722
– –
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.6B
$3.59M 5.66%
11,872
– –
RXRX icon
7
Recursion Pharmaceuticals
RXRX
$1.58B
$3.36M 5.3%
664,610
– –
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.31B
$3.1M 4.89%
49,120
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16.5B
$2.35M 3.7%
13,600
– –
LAB icon
10
Standard BioTools
LAB
$342M
$2.26M 3.56%
1,883,179
– –
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.51B
$2.22M 3.5%
102,984
– –
ARGX icon
12
argenx
ARGX
$55.2B
$1.54M 2.43%
2,800
– –
KYMR icon
13
Kymera Therapeutics
KYMR
$8.66B
$1.35M 2.12%
30,875
– –
RVMD icon
14
Revolution Medicines
RVMD
$38.5B
$708K 1.12%
19,253
– –
REPL icon
15
Replimune Group
REPL
$455M
$592K 0.93%
63,719
-350,527
-85% -$3.06M
BCYC
16
Bicycle Therapeutics
BCYC
$269M
$479K 0.76%
68,943
– –
BOLT icon
17
Bolt Biotherapeutics
BOLT
$7.4M
$337K 0.53%
58,347
-1
-0% -$7
TRDA icon
18
Entrada Therapeutics
TRDA
$254M
$330K 0.52%
49,082
– –
RANI icon
19
Rani Therapeutics
RANI
$94.8M
$254K 0.4%
493,584
– –
BSLK
20
DELISTED
Bolt Projects Holdings
BSLK
$114K 0.18%
40,597
-1
-0% -$4
AFMD
21
DELISTED
Affimed
AFMD
– –
-37,247
Closed -$26.9K
ALXO icon
22
ALX Oncology
ALXO
$262M
– –
-41,950
Closed -$26.1K
DBVT
23
DBV Technologies
DBVT
$813M
– –
-37,095
Closed -$253K
EXEL icon
24
Exelixis
EXEL
$13.9B
– –
-64,200
Closed -$2.37M
GERN icon
25
Geron
GERN
$898M
– –
-1,373,550
Closed -$2.18M
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q2 2025 Portfolio in Review

As of Q2 2025, Nan Fung Group Holdings held 35 positions worth $63.4M, down 48% from $123M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Nan Fung Group Holdings withdrew a net $60.8M in Q2 2025, closing 15 positions and reducing 3 holdings. Its most notable exit was Verona Pharma, an estimated $9.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Materials.

  • Nan Fung Group Holdings's biggest Q2 2025 reduction was Replimune Group, cutting an estimated $3.06M.
  • Nan Fung Group Holdings fully exited Verona Pharma in Q2 2025, selling an estimated $9.4M.
  • Nan Fung Group Holdings's ten largest holdings make up 88% of its $63.4M portfolio in Q2 2025.
  • Nan Fung Group Holdings opened 0 new positions and closed 15 in Q2 2025.
  • Nan Fung Group Holdings's portfolio value fell 48% quarter-over-quarter to $63.4M.

Based on Nan Fung Group Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.